OVERVIEW
OverviewMBC
Pharma, Inc. is a pharmaceutical company discovering and developing novel medicines for the treatment of oncology, bone and infectious diseases. MBC Pharma's patented technologies improve upon the benefit of known drugs by adding tissue targeting and increased cancer cell specificity and uptake.
MBC Pharma's mission is to create value through discovery and development novel therapeutics to treat important oncological, bone and infectious diseases, using the Company's platform technologies.
MBC R&D programs are based on two core proprietary discovery platforms
- Bone-targeting using bone-homing bisphosphonates conjugated to either anticancer or anti-infective drug payloads.
- First-in-Class: Human proof of concept demonstrated by MBC-11 in a Phase I clinical trial in patients with established bone lesions due to breast, prostate or cervical cancer.
- Novel platform expanding compounds are under pre-clinical development.
- First-in-Class: Human proof of concept demonstrated by MBC-11 in a Phase I clinical trial in patients with established bone lesions due to breast, prostate or cervical cancer.
-
Vitamin B6-based nucleotide pro-drugs - oncology and viral diseases indications